Lung Cancer (NSLC) more lethal if poor Vitamin D gene ( CYP2R1)

Genetic Polymorphisms in the Vitamin D Pathway and Non-small Cell Lung Cancer Survival

Pathology & Oncology Research, pp 1–7

Jinyu Kong Xiaojie Chen Jian Wang Jingxin Li Fangxiu Xu Shegan Gao Herbert Yu Biyun Qian

1. # items in Cancer-Lung  - see alsoOverview Lung cancer and vitamin D,    Cancer - After diagnosis,    Overview Cancer and vitamin D * Asian men often smoke then die of lung cancer (if you must smoke, take Vitamin D) – meta-analysis March 2019 Lung Cancer Meta-analyses {category} Lung Cancer Genetics {category} Lung Cancer Vitamin D Receptor {category} --- Wikipedia From the web

📄 Download the PDF from VitaminDWiki

Note: Trends for two additional genes

Various genetic polymorphisms have been linked to lung cancer susceptibility and survival outcomes. Vitamin D (VD) regulates cell proliferation and differentiation, inhibits tumor growth and induces apoptosis. Observations from several previous studies including our own suggest that genetic polymorphisms in the VD pathway may be associated with lung cancer risk. The aim of this study is to assess if genetic polymorphisms in the VD pathway are associated with the prognosis of non-small cell lung cancer (NSCLC). Nine single nucleotide polymorphisms (SNPs) in five genes in the VD pathway were genotyped with the TaqMan assays in 542 patients with primary NSCLC, and the relationships between these SNPs and overall survival were evaluated.

We found that SNP rs10741657 in the CYP2R1 gene was associated with the prognosis of NSCLC, especially in elderly patients and not being treated with chemotherapy. Some of the VD pathway-related genetic polymorphisms may influence the prognosis of NSCLC. More research is needed to further confirm the finding and test if VD supplements can be used for NSCLC treatment.